{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T05:11:12Z","timestamp":1790313072477,"version":"4.1.0"},"reference-count":29,"publisher":"MDPI AG","issue":"20","license":[{"start":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:00:00Z","timestamp":1760313600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: Immune checkpoint inhibitors (ICIs) have transformed cancer therapy but are often complicated by immune-related adverse events, particularly colitis. With increasing ICI use, understanding the clinical course and management of ICI-induced colitis is essential. Objectives: To characterize the clinical, endoscopic, and histological features of ICI-induced colitis and evaluate treatment outcomes, focusing on the use of corticosteroids and second-line biologicals (infliximab and vedolizumab) in a real-world setting. Methods: A retrospective cohort study was conducted at Ghent University Hospital, including 77 adult patients diagnosed with ICI-induced colitis in between 2012 and 2023. Clinical, biochemical, endoscopic, and histological data were analyzed, along with treatment response and safety outcomes. Results: Patients with ICI-induced colitis received anti-PD-1\/PD-L1 (64.9%), anti-CTLA-4 (9.1%), or combination of both (26.0%). In patients with normal endoscopic findings, histological signs of colitis were observed in 88.0%. Combination ICI therapy was associated with higher Mayo scores (p = 0.029) and increased need for biologicals (p = 0.011) compared to anti-PD-1\/PD-L1 monotherapy. Clinical response rates were 79.6% with corticosteroids and 100.0% with biologicals. Rechallenge with ICIs lead to a 17.4% relapse rate. No colitis-related deaths were observed. Conclusions: In this retrospective study, we demonstrate that random colon biopsies reveal microscopic ICI-induced colitis in most patients with absence of endoscopic disease. Combination ICI therapy predicts a corticosteroid-refractory course, supporting the need for early escalation to biologicals. ICI rechallenge appears feasible, as relapse rates were relatively low and colitis morbidity remained manageable. Prospective studies are needed to refine therapeutic strategies and improve patient outcomes.<\/jats:p>","DOI":"10.3390\/jcm14207219","type":"journal-article","created":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T11:57:42Z","timestamp":1760529462000},"page":"7219","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Immune Checkpoint-Induced Colitis: A Single-Center Retrospective Cohort Study"],"prefix":"10.3390","volume":"14","author":[{"given":"Bengt","family":"Van Holder","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Ghent University Hospital, 9000 Ghent, Belgium"},{"name":"Faculty of Medicine and Health Sciences, Ghent University, 9000 Ghent, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Vereecke","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Health Sciences, Ghent University, 9000 Ghent, Belgium"},{"name":"Department of Gastroenterology and Hepatology, Ghent University Hospital, 9000 Ghent, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Ureel","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Health Sciences, Ghent University, 9000 Ghent, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1817-7704","authenticated-orcid":false,"given":"Triana","family":"Lobat\u00f3n","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Health Sciences, Ghent University, 9000 Ghent, Belgium"},{"name":"Department of Gastroenterology and Hepatology, Ghent University Hospital, 9000 Ghent, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0736-2034","authenticated-orcid":false,"given":"Anne","family":"Hoorens","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Health Sciences, Ghent University, 9000 Ghent, Belgium"},{"name":"Department of Pathology, Ghent University Hospital, 9000 Ghent, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amber","family":"Lievens","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Health Sciences, Ghent University, 9000 Ghent, Belgium"},{"name":"Department of Pathology, Ghent University Hospital, 9000 Ghent, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Truyens","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Health Sciences, Ghent University, 9000 Ghent, Belgium"},{"name":"Department of Gastroenterology and Hepatology, Ghent University Hospital, 9000 Ghent, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Rottey","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Ghent University Hospital, 9000 Ghent, Belgium"},{"name":"Faculty of Medicine and Health Sciences, Ghent University, 9000 Ghent, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karim","family":"Vermaelen","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Health Sciences, Ghent University, 9000 Ghent, Belgium"},{"name":"Respiratory Medicine, Ghent University Hospital, 9000 Ghent, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venita","family":"D\u2019Cruz","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Ghent University Hospital, 9000 Ghent, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0126-2929","authenticated-orcid":false,"given":"Jeroen","family":"Geldof","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Health Sciences, Ghent University, 9000 Ghent, Belgium"},{"name":"Department of Gastroenterology and Hepatology, Ghent University Hospital, 9000 Ghent, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5286-3519","authenticated-orcid":false,"given":"Celine","family":"Jacobs","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Ghent University Hospital, 9000 Ghent, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1508-7263","authenticated-orcid":false,"given":"Eline","family":"Naert","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Ghent University Hospital, 9000 Ghent, Belgium"},{"name":"Faculty of Medicine and Health Sciences, Ghent University, 9000 Ghent, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elien","family":"De Mulder","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Ghent University Hospital, 9000 Ghent, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5523-6537","authenticated-orcid":false,"given":"Michael","family":"Saerens","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Ghent University Hospital, 9000 Ghent, Belgium"},{"name":"Faculty of Medicine and Health Sciences, Ghent University, 9000 Ghent, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,10,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s43018-024-00730-3","article-title":"Clinical and translational attributes of immune-related adverse events","volume":"5","author":"Suijkerbuijk","year":"2024","journal-title":"Nat. Cancer"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-Related Adverse Events Associated with Immune Checkpoint Blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1002\/cncr.34543","article-title":"Immune checkpoint inhibitor gastritis is often associated with concomitant enterocolitis, which impacts the clinical course","volume":"129","author":"Haryal","year":"2023","journal-title":"Cancer"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1016\/j.cgh.2020.01.033","article-title":"Management of Patients with Immune Checkpoint Inhibitor-Induced Enterocolitis: A Systematic Review","volume":"18","author":"Collins","year":"2020","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1200\/JCO.2015.60.8448","article-title":"Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center","volume":"33","author":"Horvat","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Haanen","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_8","unstructured":"Odze, R.D., and Goldblum, J.R. (2022). Surgical Pathology of the GI Tract, Liver, Biliary Tract and Pancreas, Elsevier. [4th ed.]."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ejca.2023.03.025","article-title":"Position statement on the management of the immune checkpoint inhibitor-induced colitis via multidisciplinary modified Delphi consensus","volume":"187","author":"Desmedt","year":"2023","journal-title":"Eur. J. Cancer"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e002435","DOI":"10.1136\/jitc-2021-002435","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events","volume":"9","author":"Brahmer","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of Immune-Related Adverse Events in Patients Treated with Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e007409","DOI":"10.1136\/jitc-2023-007409","article-title":"Corticosteroid-resistant immune-related adverse events: A systematic review","volume":"12","author":"Daetwyler","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"102440","DOI":"10.1016\/j.ctrv.2022.102440","article-title":"Immune checkpoint Inhibitor-Induced diarrhea and Colitis: Incidence and Management. A systematic review and Meta-analysis","volume":"109","author":"Nielsen","year":"2022","journal-title":"Cancer Treat. Rev."},{"key":"ref_14","first-page":"S68","article-title":"S0137: Comparative study of vedolizumab and infliximab treatment in patients with immune-mediated diarrhea and colitis","volume":"115","author":"Zou","year":"2020","journal-title":"Am. J. Gastroenterol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1093\/ecco-jcc\/jjw092","article-title":"An Overview of the Mechanism of Action of the Monoclonal Antibody Vedolizumab","volume":"10","author":"Wyant","year":"2016","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s00262-017-1962-6","article-title":"Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis","volume":"66","author":"Bergqvist","year":"2017","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/s40425-018-0461-4","article-title":"Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor-induced colitis: A multi-center study","volume":"6","author":"Ali","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"S119","DOI":"10.1053\/j.gastro.2019.11.271","article-title":"P086: Effectiveness of vedolizumab in patients with refractory immunotherapy-related colitis: A case series","volume":"158","author":"Harris","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: Guidelines for reporting observational studies","volume":"370","author":"Altman","year":"2007","journal-title":"Lancet"},{"key":"ref_20","unstructured":"(2018). A Phase 1\/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers (Standard No. 2018\u2013000340-26)."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Lieverse, R.I.Y., Van Limbergen, E.J., Oberije, C.J.G., Troost, E.G.C., Hadrup, S.R., Dingemans, A.-M.C., Hendriks, L.E.L., Eckert, F., Hiley, C., and Dooms, C. (2020). Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients: ImmunoSABR, a multicentre, randomised controlled open-label phase II trial. BMC Cancer, 20.","DOI":"10.1186\/s12885-020-07055-1"},{"key":"ref_22","unstructured":"(2016). A Study of Budigalimab (ABBV-181) in Participants with Advanced Solid Tumors (Standard No. NCT03000257)."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s00262-022-03253-x","article-title":"Pembrolizumab, radiotherapy, and an immunomodulatory five-drug cocktail in pretreated patients with persistent, recurrent, or metastatic cervical or endometrial carcinoma: Results of the phase II PRIMMO study","volume":"72","author":"Tuyaerts","year":"2023","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e000278","DOI":"10.1136\/esmoopen-2017-000278","article-title":"Immune checkpoint inhibition-related colitis: Symptoms, endoscopic features, histology and response to management","volume":"3","author":"Rozeman","year":"2018","journal-title":"ESMO Open"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1001\/jamaoncol.2022.5041","article-title":"Association of Immune-Related Adverse Event Management with Survival in Patients with Advanced Melanoma","volume":"8","author":"Verheijden","year":"2022","journal-title":"JAMA Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e003277","DOI":"10.1136\/jitc-2021-003277","article-title":"Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: A two-center observational study","volume":"9","author":"Zou","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"ref_27","unstructured":"(2021). Vedolizumab for Immune Mediated Colitis (Standard No. NCT04797325)."},{"key":"ref_28","unstructured":"M.D.A.C. Center (2025, August 16). Infliximab or Vedolizumab in Treating Immune Checkpoint Inhibitor-Related Colitis in Patients with Genitourinary Cancer or Melanoma. NCT04407247. Available online: https:\/\/www.mdanderson.org\/patients-family\/diagnosis-treatment\/clinical-trials\/clinical-trials-index\/clinical-trials-detail.ID2019-0276.dir.html\/1000."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2738","DOI":"10.1200\/JCO.19.00320","article-title":"Resumption of Immune Checkpoint Inhibitor Therapy After Immune-Mediated Colitis","volume":"37","author":"Ali","year":"2019","journal-title":"J. Clin. Oncol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/20\/7219\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T12:19:23Z","timestamp":1760530763000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/20\/7219"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,13]]},"references-count":29,"journal-issue":{"issue":"20","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["jcm14207219"],"URL":"https:\/\/doi.org\/10.3390\/jcm14207219","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,13]]}}}